Shinobi Therapeutics

0 followers


Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.


Org chart

Dan Kemp
Chief Executive Officer
Collapse
Bhanu Iyer
VP US Operations & HR
Ryosuke Gonotsubo
Chief Of Staff
Tobias Deuse
Co-founder
Molly Cole
Head Of BD And R&d Strategy

Teams

This company has no teams yet